[1]
|
J. S. Schindler and J. H. Kelly, “Swallowing Disorders in the Elderly,” Laryngoscope, Vol. 112, No. 4, 2002, pp. 589-602.
|
[2]
|
J. C. Ofstehage and K. Magilvy, “Oral Health and Aging,” Geriatric Nursing, Vol. 81, No. 7, 1986, pp. 238- 241.
|
[3]
|
G. Motola, F. Russo, F. Mazzeo, B. Rinaldi, A. Capuano, F. Rossi and A. Filipelli, “Over-the-Counter Oral Non-steroidal Anti-Inflammatory Drugs: A Pharmacoepidemi-ologic Study in Southern Italy,” Advances in Therapy, Vol. 18, No. 5, 2001, pp. 216-222.
|
[4]
|
L. Yang, S. C. James and A. Joseph, “Colon-Specific Drug Delivery: New Approaches and in Vitro/in Vivo Evaluation,” International Journal of Pharmaceutics, Vol. 235, No. 1-2, 2002, pp. 1-15.
|
[5]
|
K. D. Tripathi, “Essentials of Medical Pharmacology,” 5th Edition, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 2003.
|
[6]
|
L. Li, S. Gorukanti, Y. M. Choi and K. H. Kim, “Rap-id-Onset Intranasal Delivery of Anticonvulsants: Phar-macokinetic and Pharmacodynamic Evaluation in Rabbits,” International Journal of Pharmaceutics, Vol. 199, No. 1, 2000, pp. 65-76.
|
[7]
|
B. Alldredge, A. Gelb, S. Isaacs, M. Corry, F. Allen, S. Ulrich, M. Gottwald, N. O’Neil, J. Neuhaus, M. Segal and D. A. Lowenstein, “Comparison of Lorazepam, DZ, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus,” New England Journal of Medicine, Vol. 345, No. 9, 2001, pp. 631-637.
|
[8]
|
C. O’Dell, “What Do We Tell Parents of a Child with Simple or Complex Febrile Seizures?” In: T. Z. Baram, and S. Shinnar, Eds., Febrile Seizures, San Diego, CAS Academic Press, 2002, pp. 305-316.
|
[9]
|
C. O’Dell, S. Shinnar, K. Ballaban-Gil, M. Hornick, M. Sigalova, H. Kang and S. Moshe, “Rectal DZ Gel in the Home Management of Seizures in Children,” Pediatric Neurology, Vol. 33, No. 3, 2005, pp. 166-172.
|
[10]
|
G. Abdelbary and R. H. Fahmy, “Diazepam-Loaded Solid lipid Nanoparticles: Design and Characterization,” AAPS PharmSciTech, Vol. 10, No. 1, 2009, pp. 211-219.
|
[11]
|
E. Bechgaard, S. Gizurarason and R. K. Hjortkjaer, “Pharmacokinetic and Pharmacodynamic Response after Intranasal Administration of Diazepam to Rabbits,” Journal of Pharmacy Pharmacology, Vol. 49, No. 8, 1997, pp. 747-750.
|
[12]
|
S. Gizurarson, F. K. Gudbrandsson, H. Jonsson and E. Bechgaard, “Intranasal Administration of Diazepam Aiming at the Treatment of Acute Seizures: Clinical Trials in Healthy Volunteers,” Biological and Pharmaceutical Bulletin, Vol. 22, No. 4, 1999, pp. 425-427.
|
[13]
|
E. Rey, J. M. Treluyer and G. Pons, “Pharmacokinetic Optimization of Benzodiazepine Therapy for Acute Sei-zures. Focus on Delivery Routes,” Clinical Pharmacoki-netics, Vol. 36, No. 6, 1999, pp. 409-424.
|
[14]
|
F. U. Knudsen, “Rectal Administration of Diazepam in Solution in the Acute Treatment of Convulsions in Infants and Children,” Archives of Disease in Childhood, Vol. 54, No. 11, 1979, pp. 855-857.
|
[15]
|
E. Norris, O. Marzouk, A. Nunn, J. Mclntyre and I. Choonara, “Respiratory Depression in Children Receiving Diazepam for Acute Seizures: A Prospective Study,” De-velopmental Medicine and Child Neurology, Vol. 41, No. 5, 1999, pp. 340-343.
|
[16]
|
B. R. Ogutu, C. R. J. C. Newton, J. Crawley, S. N. Mu-chohi, G. O. Otieno, G. Edwards, K. Marsh and G. O. Kokwaro, “Pharmacokinetics and Anticonvulsant Effects of Diazepam in Children with Severe Falciparum Malaria and Convulsions,” British Journal of Clinical Pharma-cology, Vol. 53, No. 1, 2002, pp.49-57.
|
[17]
|
C. W. Graham, R. R. Pagano and J. T. Conner, “Pain and Clinical Thrombophlebitis Following Intravenous Diaze-pam and Lorazepam,” Anaesthesia, Vol. 33, No. 2, 1978, 188-91.
|
[18]
|
C. Lehmann and G. L. Wannarka, “Bioavailability and Dose Proportionality of Intramuscular Diazepam Admi-nistered by Autoinjector,” Journal of Clinical Pharma-cology, Vol. 48, No. 4, 2008, pp. 436-444.
|
[19]
|
J. G. Hardman, L. E. Limbard and A. G. Gilman, “The Pharmacological Basis of Therapeutics,” 10th Edition, McGraw-Hill Medical Publishing Division, New Delhi, 2001.
|
[20]
|
A. J. Hoogstrate, J. C. Verhoef, B. Tuk and A. Pijpers, “In-Vivo Buccal Delivery of Fluorescin Isothiocyanate- Dextran 4400 with Glycodeoxycholate as an Absorption Enhancer in Pig,” Journal of Pharmaceutical Sciences, Vol. 85, No. 5, 1996, pp. 457-460.
|
[21]
|
T. Keiko, O. Yasuko, N. Tsuneji, L. Thorseinn and T. Kozo, “Buccal Absorption of Ergotamine Tartrate Using the Bioadhesive Tablet System in Guinea-Pigs,” Interna-tional Journal of Pharmaceutics, Vol. 238, No. 1-2, 2002, pp. 161-170.
|
[22]
|
B. S. Kuchekar, S. B. Bhise and V. Arumugam, “Design of Fast Dissolving Tablet,” Indian Journal of Pharma-ceutical Education, Vol. 35, No. 4, 2001, pp. 150-152.
|
[23]
|
T. Loftsson, “Cyclodextrins and the Biopharmaceutics Classification System of Drugs,” Journal of Inclusion Phenomenon, Vol. 44, No. 1-4, 2002, pp. 63-67.
|
[24]
|
M. Sugimoto, S. Narisawa, K. Matsubara, H. Yoshino, M. Nakano and T. Handa, “Effect of Formulated Ingredients on Rapidly Disintegrating Oral Tablets Prepared by the Crystalline Transition Method,” Chemical and Pharma-ceutical Bulletin, Vol. 54, No. 2, 2006, pp. 175-180.
|
[25]
|
H. N. Joshi, R. W. Tejwani, M. Davidovich, V. P. Saha-srabudhe, M. Jemal, M. S. Bathala, S. A. Varia and A. T. M. Serajuddin, “Bioavailability Enhancement of a Poorly Water-Soluble Drug by Solid Dispersion in Polyethylene Glycol-Polysorbate 80 Mixture,” International Journal of Pharmaceutics, Vol. 269, No. 1, 2004, pp. 251-258.
|
[26]
|
P. C. Sheen, V. K. Khetarpal, C. M. Cariola and C. E. Rowlings, “Formulation Studies of a Poorly Water-Soluble Drug in Solid Dispersions to Improve Bioavailability,” International Journal of Pharmaceutics, Vol. 118, No. 2, 1995, pp. 221-227.
|
[27]
|
P. Mura, A. Manderioli, G. Bramanti and L. Ceccarelli, “The Properties of Solid Dispersions of Naproxen in Various Polyethylene Glycols,” Drug Development and Industrial Pharmacy, Vol. 22, No. 9-10, 1996, pp. 909- 916.
|
[28]
|
T. Kai, Y. Akiama, S. Nomura and M. Sato, “Oral Ab-sorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique,” Chemical and Pharmaceutical Bulletin, Vol. 44, No. 3, 1996, pp. 568-571.
|
[29]
|
C. Leuner and J. Dressman, “Improving Drug Solubility for Oral Delivery Using Solid Dispersions,” European Journal of Pharmaceutical Sciences, Vol. 50, No. 1, 2000, pp. 47-60.
|
[30]
|
T. Loftsson, “Cyclodextrin Complexation,” US Patent, 1995, 5472954.
|
[31]
|
M. Gohel, M. Patel, A. Amin, R. Agarwal, R. Dave and N. Bariya, “Formulation Design and Optimization of Mouth Dissolve Tablets of Nimesulide Using Vacuum Drying Technique,” AAPS PharmSciTech, Vol. 5, No. 3, 2004, Article 36.
|
[32]
|
S. Chutimaworapan, G. C. Ritthidej, E. Yonemochi, T. Oguchi and K. Yamamoto, “Effect of Water-Soluble Car-riers on Dissolution Characteristics of Nifedipine Solid Dispersions,” Drug Development and Industrial Phar-macy, Vol. 26, No. 11, 2000, pp. 1141-1150.
|
[33]
|
H. G. Choi, K. M. Kim, H. W. Jun, B. K. Yoo and C. S. Yong, “Improvement of Dissolution and Bioavailability of Nifedipine by Inclusion in Hydroxypropyl-β-Cyclo- dextrin,” Drug Development and Industrial Pharmacy, Vol. 29, No. 10, 2003, pp. 1085-1094.
|
[34]
|
H. J. Ahn, K. M. Kim, S. J. Choi and C. K. Kim, “Effects of Cyclodextrin Derivatives on Bioavailability of Keto-profen,” Drug Development and Industrial Pharmacy, Vol. 23, No. 4, 1997, pp. 397-401.
|
[35]
|
A. Latrofa, G. Trapani, M. Franco, M. Serra, M. Muggi-roni, F. P. Franizzi, A. Cutrignelli and G. Liso, “Com-plexation of Phenytoin with Some Hydrophilic Cyclodex-trins: Effect on Aqueous Solubility, Dissolution Rate and Anti-Convulsant Activity in Mice,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 52, No. 1, 2001, pp. 65-73.
|
[36]
|
T. Higuchi and K. A. Connors, “Phase-Solubility Tech-niques,” Advances in Analytical Chemistry and Instru-mentation, Vol. 53, No. 4, 1965, pp. 117-212.
|
[37]
|
Y. Watanable, K. I. Koizumi, Y. Zama, M. Kiriyama and M. Matsumoto, “New Compressed Tablet Rapidly Disin-tegrating in Saliva in the Mouth Using Crystalline Cellu-lose and a Disintegrant,” Biological and Pharmaceutical Bulletin, Vol. 18, No. 9, 1995, pp. 1308-1310.
|
[38]
|
K. I. Koizumi, Y. Watanable, K. Morita, N. Utoguchi and M.Matsumoto, “New method for preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material,” International Journal of Pharmaceutics, Vol. 152, No. 1, 1997, pp. 127- 131.
|
[39]
|
H. A. Lieberman, L. Lachman and J. B. Schwartz, “Pharmaceutical Dosage Forms: Tablets Vol. 2,” 2nd Edition, Marcel Dekker, New York, 1990, pp. 1-71.
|
[40]
|
Y. Bi, H. Sunada, Y. Yonezawa, K. Danjo, A. Otsuka and K. Iida, “Preparation and Evaluation of a Compressed Tablet Rapidly Disintegrating in the Oral Cavity,” Chem-ical and Pharmaceutical Bulletin, Vol. 44, No. 11, 1996, pp. 2121-2127.
|
[41]
|
R. C. Rowe, P. J. Sheskey and P. J. Weller, “Handbook of Pharmaceutical Excipients,” 4th Edition, Pharmaceutical Society of Great Britain, London, 2003.
|
[42]
|
K. A. Khan, “The Concept of Dissolution Efficiency,” Journal of Pharmacy and Pharmacology, Vol. 27, No. 1, 1975, pp. 48-49.
|